An investigation of the proteoglycan metabolism of mature equine articular cartilage and its regulation by interleukin-1.

This research aimed to understand how a protein known as human recombinant interleukin-1 beta (rhIL-1 beta) affects the metabolism of certain molecules called proteoglycans in the articular cartilage of horses. The results revealed that the protein does prevent the creation of new proteoglycan molecules, but doesn’t change their size or the rate at which they are replaced in the cartilage. It also suggests that interleukin-1, which increases during inflammation, can alter the proteoglycan composition in horse cartilage by promoting the creation of fewer, unusually composed proteoglycan molecules.

Study Purpose and Methods

• The study’s goal was to explore how human recombinant interleukin-1 beta (rhIL-1 beta), a type of protein, affects the metabolism of proteoglycans within mature equine articular cartilage.
• Proteoglycans are vital molecules involved in the structure and function of cartilage in the joints of animals. Understanding how they are affected by rhIL-1 beta could provide important insights into the health and diseases of joints.
• The researchers used cultures of full thickness explants/cross-section of articular cartilage from horses aged 3-21 years.
• The effects of rhIL-1 beta on proteoglycan synthesis, size, heterogeneity, and turnover rate were examined, as well as the structure of proteoglycan fragments released into a culture medium.

Findings

• RhIL-1 beta was found to inhibit proteoglycan synthesis in the horse cartilage, regardless of the horse’s age. This means it prevented the creation of new proteoglycan molecules.
• Despite this inhibition, rhIL-1 beta did not change the hydrodynamic size (the measure of how a particle moves or behaves in a fluid) or electrophoretic heterogeneity (variability when a charged particle moves in an electrical field) of the proteoglycans.
• Interestingly, the sulphation pattern (a process which involves adding sulphate groups to molecules) of newly synthesised proteoglycans was significantly altered with the presence of rhIL-1 beta.
• Moreover, rhIL-1 beta showed no effect on the rate of turnover (replacement) of freshly created or present proteoglycans in the horse’s cartilage.
• Lastly, the structure of proteoglycan fragments released into a culture medium was not influenced by rhIL-1 beta.

Implications

• The study suggests that interleukin-1, a molecule whose levels increase during events like inflammation, can possibly change the proteoglycan composition within normal equine cartilage.
• This change isn’t caused by stimulating enzymes that break down present proteoglycans, but rather by driving the accumulation of fewer newly created proteoglycan molecules that feature an abnormal composition.
• Thus, the findings provide new insights into how inflammation might affect cartilage health and could have implications for understanding and treating joint diseases.